Oral cancer is the sixth most common type of cancer worldwide and in the U.S., one person dies every hour from the disease. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection.
Taiho Pharmaceutical Co., Ltd.(Japan) and Servier (France) announced on June 15 that they have entered into an exclusive license agreement on June 12, 2015 for the development and commercialization of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride) in Europe and other countries.
Data from the pivotal coBRIM Phase III study, presented by Lead Investigator Dr James Larkin today at the American Society of Clinical Oncology (ASCO) annual meeting, demonstrate that Roche’s investigational MEK inhibitor cobimetinib, used in combination with BRAF inhibitor vemurafenib, typically offers people with previously untreated advanced metastatic melanoma (BRAFV600 mutation-positive unresectable or metastatic) one full year (median 12.3 months) without their disease worsening.
Researchers from the Abramson Cancer Center of the University of Pennsylvania and Penn's Perelman School of Medicine will present results from several clinical trials and other key studies during the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 through June 2.
Researchers at Oregon State University are pursuing a new concept in treatment of epithelial cancer, especially head and neck cancer, by using two promising "analogs" of an old compound that was once studied as a potent anti-tumor agent, but long ago abandoned because it was too toxic.
Mouth and throat cancers are the fastest rising cancers today. They account for over 40,000 cases per year in the U.S. The American Cancer Society estimates that there will be 121,790 new cases of head and neck cancer diagnosed in 2015 and 14,240 deaths. These numbers include tongue cancer, throat cancers caused by the human papillomavirus or HPV, voice box cancer, melanoma of the face and thyroid cancers.
When oral and oropharyngeal cancers (cancers of the mouth and upper throat) are detected and treated early in their development, survival rates can improve significantly. Regular oral cancer examinations performed by your oral health professional remain the best method for detecting oral cancer in its early stages.
A compound found in green tea may trigger a cycle that kills oral cancer cells while leaving healthy cells alone, according to Penn State food scientists. The research could lead to treatments for oral cancer, as well as other types of cancer.
Improving oral health is a leading population health goal; however, curricula preparing health professionals have a dearth of oral health content and clinical experiences. Funded by a grant from the Health Resources and Service Administration, New York University College of Nursing's Teaching Oral-Systemic Health Program is working to build interprofessional oral health workforce capacity which addresses a significant public health issue, increases oral health care access, and improves oral-systemic health across the lifespan.
DiaCarta, Inc., a privately-held biotechnology company raised $8 million in Series A financing from BVCF (BioVeda China Fund). Proceeds from Series A financing will be used to expand the product portfolio and support global commercialization. Dr. Weixin Xu of BVCF will join DiaCarta board of directors.
Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the Abramson Cancer Center of the University of Pennsylvania.
UCLA research could lead to a simple saliva test capable of diagnosing — at an early stage — diabetes and cancer, and perhaps neurological disorders and autoimmune diseases.
Although oral hormonal therapy is known to substantially reduce breast cancer recurrence in women with hormone receptor-positive tumors, about one-half of patients fail to take their medications as directed. A new study by Columbia University Medical Center researchers has found that the introduction of generic aromatase inhibitors (the most common type of hormone therapy), which are considerably less expensive than their brand name counterparts, increased treatment adherence by 50 percent.
Pre-treatment pain intensity is an independent survival predictor for patients with head and neck cancer, according to new research published in The Journal of Pain, the peer-reviewed publication of the American Pain Society.
A new Aspen Dental office is opening in Estero, FL on Thursday, October 23. Located at 22911 Lyden Drive Ste B, the conveniently located practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.
A new Aspen Dental office is opening in Hermitage, TN on Thursday, October 2. Located at 4054 Lebanon Pike, the conveniently located practice will provide dental services that range from implant services and dentures to general dentistry and restoration.
A new Aspen Dental office is opening in Sebring, FL on Thursday, October 2. Located at 1855 US 27 North, the conveniently located practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.
A new Aspen Dental office is opening in Selinsgrove, PA on Thursday, September 18. Located at 1597 N. Susquehanna Trail, the conveniently located practice will provide dental services that range from dentures and preventive care to general dentistry and restoration.
Research published yesterday indicates that recurrence of human papillomavirus (HPV)-induced cancers affecting the oropharynx (the area of the throat just behind the mouth) can be predicted by blood and saliva tests that screen for DNA fragments from HPV that have been shed by cancer cells.
Research conducted at the Florida campus of The Scripps Research Institute has discovered links between a set of genes known to promote tumor growth and mucoepidermoid carcinoma, an oral cancer that affects the salivary glands. The discovery could help physicians develop new treatments that target the cancer's underlying genetic causes.
Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found.